Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

Completed · Phase 2 · Has a placebo group

Conditions studied: Primary Open-Angle Glaucoma, Ocular Hypertension

In brief

The objective of this Phase 2 study is to evaluate whether the Bimatoprost Ocular Insert is non-inferior to that of timolol ophthalmic solution (0.5%) at 12 weeks.

Key facts

Study ID

NCT01915940

Run by

ForSight Vision5, Inc.

People needed

169

Starts

2013-10-23

Expected to finish

2014-11-14

Last updated by the study team

2018-04-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sall Medical Research Center — Artesia, California, United States
• Scripps Clinic Torrey Pines — La Jolla, California, United States
• Eye Research Foundation — Newport Beach, California, United States
• UC Davis Dept of Ophthalmology & Vision Science — Sacramento, California, United States
• Coastal Research Associates — Atlanta, Georgia, United States
• Clayton Eye Center — Morrow, Georgia, United States
• Ophthalmology Consultants — St Louis, Missouri, United States
• UNC Kittner Eye Center — Chapel Hill, North Carolina, United States
• Apex Eye — Madeira, Ohio, United States
• Ophthalmology Associates PC — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.